Inflammatory processes in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 26, Issue 4, 2002, Pages 459-470

  McGeer, P L ^a   McGeer, E G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Astrocytes; Complement; Cyclooxygenase; Microglia; Superoxide dismutase

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTE; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; GENETIC ASSOCIATION; INFECTION; INFLAMMATORY DISEASE; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION;

EID: 0036787810     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10191     Document Type: Review

References (127)

1. Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer PL. Expression of intracellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol 1993;85:628-634.
2. Akiyama H, McGeer PL. Brain microglia constitutively express β-2 integrins. J Neuroimmunol 1990;30:81-93.
3. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001;57:1282-1289.
4. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, Przedborski S. Increased expression of the pro inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-185.
5. Almer G, Vukosavic S, Romero N, Przedborski S. Inducible nitric oxide synthase upregulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999;72:2415-2425.
6. Andersen PM. Genetics of sporadic ALS. Amyotroph Lat Scler Other Motor Neuron Disord 2001;2(11 Suppl):537-541.
7. Andersen PM, Nilsson P, Ala-Hurula V, Keranen ML, Tarvainen I, Haltia T, Nilsson L, Binzer M, Forsgren L, Marklund SL. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995;10:61-66.
8. Andrews WD, Alchalabi A, Garson JA. Lack of evidence for HTLV tax-rex DNA in motor neurone disease. J Neurol Sci 1997;153:86-90.
9. Andrews WD, Tuke PW, Al-Chalabi A, Gaudin P, Ijaz S, Parton MJ, Garson JA. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol 2000;61:527-532.
10. Anneser JMH, Cookson MR, Ince PG, Shaw PJ, Borasio GD. Glial cells of the spinal cord and subcortical white matter upregulate nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp Neurol 2001;171:418-421.
11. Aoki M, Lin CLG, Rothstein JD, Geller BA, Hosler BA, Munsat TL, Horvitz HR, Brown RH. Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol 1998;5:645-653.
12. Appel SH, Smith RG, Alexianu MF, Engelhardt JI, Stefani E. Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Adv Neurol 1995;68:47-57.
13. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993;7:111-118.
14. Barneoud P, Curet O. Beneficial effects oflysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999;155:243-251.
15. Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, Bauer J, Fiebich BL. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997;243:726-731.
16. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Lowal NW, Brown RH Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:646-654.
17. Bensimon G, Lacomblez L, Meininger V, and the ALS/ Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
18. Berger MM, Kopp N, Vital C, Redl B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequence in spinal cord of patients with ALS. Neurology 2000;54:20-25.
19. Bogdanov MB, Ramos LE, Xu ZS, Beal MF. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998;71:1321-1324.
20. Boyle EA, McGeer PL. Cellular immune reaction in multiple sclerosis plaques. Am J Pathol 1990;137:575-584.
21. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-1854.
22. Butterfield DA, Kanski J. Brain protein oxidation in agerelated neurodegenerative disorders that are associated with aggregated proteins. Mech Aging Dev 2001;122:945-962.
23. Chavany C, Vicarioabejon C, Miller G, Jendoubi M. Transgenic mice for interleukin 3 develop motor neuron degeneration associated with autoimmune reaction against spinal cord motor neurons. Proc Natl Acad Sci U S A 1998;95:11354-11359.
24. Chous SM, Han CY, Wang HS, Vlassara H, Bucala R. A receptor for advanced glycosylation endproducts (AGEs) is colocalized with neurofilament-bound AGEs and SOD1 in motoneurons of ALS: immunohistochemical study. J Neurol Sci 1999;169:87-92.
25. Cleveland DW, Bruijn LI, Wong PC, Marszalek JR, Vechio JD, Lee MK, Xu XS, Borchelt DR, Sisodia SS, Price DL. Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Neurology 1996;47(4 Suppl 2):S54-S61.
26. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev 2001;2:806-819.
27. Colton CA, Gilbert DI. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987;223:284-288.
28. Corson LB, Strain JJ, Culotta VC, Cleveland DW. Chaperonefacilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci U S A 1998;95:6261-6366.
29. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu.Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995;676:25-40.
30. Davis RL, Robertson DM, editors. Textbook of neuropathology. 2nd ed. Baltimore: Williams & Wilkins; 1991. p 141-163.
31. Del Rio Hortega P. El 'tercer elemento' de los centros nerviosos. Poder fagocitario y movilidad de la microglia. Bol Soc Esp Biol Ano 1919;9:154-166.
32. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alphatocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis (ALS). Amyotroph Lat Scler Other Motor Neuron Disord 2001;2:9-18.
33. Drachman DB. Does autoimmunity play a role in amyotrophic lateral sclerosis? In: Braus RH Jr, Meininger V, Swash M, editors. Amyotrophic lateral sclerosis. London: Martin Dunitz; 2000. p 309-316.
34. Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000;48:792-795.
35. Eisen A, Steward H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. J Can Sci Neurol 1993;20:297-301.
36. Engelhardt JI, Appel SH, Killian JM. Experimental autoimmune motor neuron disease. Ann Neurol 1989;26:368-376.
37. Engelhardt JI, Appel SH, Killian JM. Motor neuron destruction in guinea pigs immunized with bovine spinal cord ventral horn homogenate: experimental autoimmune gray matter disease. J Neuroimmunol 1990;27:21-31.
38. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993;50:30-36.
39. Feeney SJ, McKelvie PA, Austin L, Jean-Francois MJB, Kapsa R, Tombs SM, Byrne E. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis. Muscle Nerve 2001;24:1510-1519.
40. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, Macgarvey U, Kowall NW, Brown RH, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.
41. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, Beal ME. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997;42:326-334.
42. Frank KM, Coccia C, Drachman DB, Rothstein JD. COX-2 inhibition prolongs survival in a transgenic mouse model of ALS. Soc Neurosci Abstr 2001;31:107.6
43. Fraser H, Behan W, Chree A, Crossland G, Behan P. Mouse innoculation studies reveal no transmissible agent in amyotrophic lateral sclerosis. Brain Pathol 1996;6:89-99.
44. Giraud P, Kopp N, Lina B, Chazot G. Amyotrophic lateral sclerosis: a role for enteroviruses? Rev Neurol 2000;156:352-356.
45. Giulian D, Haverkamp LJ, Yu JH, Harshin WL, Li J, Kirkpatrick J, Kuo Y-M, Roher AE. Specific domains of β-amyloid from Alzheimer plaque elicit neuronal killing in human microglia. J Neurosci 1996;16:6021-6037.
46. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990;250:1593-1596.
47. Gooch CL, Harati Y. Motor unit number estimation, ALS and clinical trials. Amyotroph Lat Scler Other Motor Neuron Disord 2000;1:71-82.
48. Grewal RP, Morgan TE, Finch CE. ClqB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci Lett 1999;271:65-67.
49. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
50. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
51. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, Hosler BA, Sagie T, Skaug J, Nasir J, Brown RH Jr, Scherer SW, Rouleau GA, Hayden MR, Ikeda J-E. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001;29:166-173.
52. Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998;53:66-77.
53. Hall ED, Ooseveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249-256
54. Haymaker W, Adams RD, editors. Histology and histopathology of the nervous system. Springfield, Illinois: Charles C Thomas; 1982. p 1150-1173.
55. Hayward C, Colville S, Swingler RJ, Brock DJH. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 1999;52:1899-1901.
56. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28:254-260.
57. Ichitani Y, Shi T, Haeggstrom JZ, Samuelsson B, Hokfelt T. Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: an in situ hybridization study. Neuroreport 1997;8:2949-2952.
58. Jones CT, Swingler RJ, Simpson SA, Brock DJH. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995;32:290-292.
59. Kato S, Shimoda M, Watanabe Y, Nakashima K, Takahashi K, Ohama E. Familial amyotrophic lateral sclerosis with a two base pair deletion in superoxide dismutase 1 gene: multisystem degeneration with intracytoplasmic hyaline inclusions in astrocytes. J Neuropathol Exp Neurol 1996;55:1089-1101.
60. Kato S, Takikawa M, Nakashima K, Hirano A, Cleveland DW, Kusaka H, Shibata N, Kato M, Nakano I, Ohama E. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lat Scler Other Motor Neuron Disord 2000;1:163-184.
61. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691-707.
62. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, Waeg G, Mattson MP. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997;80:685-696.
63. Klegeris A, McGeer PL. Interaction of various intrasignalling mechanisms involved in mononuclear phagocyte toxicity towards neuronal cells. J Leukoc Biol 2000;67:127-133.
64. Klegeris A, McGeer PL. Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. J Neuroimmunol 1994;53:83-90.
65. Klegeris A, Walker DG, McGeer PL. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol 1997;78:152-161.
66. Kunst CB, Mezey E, Brownstein MJ, Patterson D. Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet 1997;15:91-94.
67. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
68. Ladecola C, Niwa K, Nogawa S, Zhao XR, Nagayama M, Araki E, Morham S, Ross ME. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 2001;98:1294-1299.
69. Lampson LA, Kushner PD, Sobel RA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann Neurol 1990;28:365-372.
70. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of A beta 1-42. J Neurochem 2001;78:413-416.
71. Levine JB, Kong JM, Nadler M, Xu ZS. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 1999;28:215-224.
72. Li M, Oan VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee J-P, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-339.
73. Liu R, Althaus JS, Ellerbrock BR, Becker DA, Guerney ME. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1998;44:763-770.
74. Louwerse ES, Weverling GJ, Bossuyt PM, Meyes FE, de Jong JM. Randomized double-blind controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-564.
75. Luber-Narod J, Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett 1988;94:265-273.
76. McGeer PL. Cyclooxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 2000;17:1-11.
77. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 1988;76:550-557.
78. McGeer PL, McGeer EG. Autotoxicity and Alzheimer disease. Arch Neurol 2000;57:789-790.
79. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001;22:799-809.
80. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative disease. Brain Res Rev 1995;21:195-218.
81. Meininger V, Lacomblez L, Salachas F. What has changed with riluzole? J Neurol 2000;247:19-22.
82. Metchnikoff E. Lecons sur la pathologie comparée de l'inflammation. Paris: Masson; 1892.
83. Miller RG, Moore D, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jaclson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-858.
84. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, Quien A, Murphy J, Brinkman J, Burns D, Parsons J, Braiman J, Kelkar P, Hartsock L, Heffner M, Moses D. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-1388.
85. Morrison BM, Morrison JH. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Brain Res Rev 1999;29:121-135.
86. Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001;57:995-1001.
87. Muir P, Nicholson F, Spencer GT, Ajetynmobi JF, Starkey WG, Khan M, Archard LC, Cairns NJ, Anderson VER, Leigh PN, Howard RS, Banatvala JE. Enterovirus infection of the central nervous system of humans - lack of association with chronic neurological disease. J Gen Virol 1996;77:1469-1476.
88. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
89. Nobile-Orazio E, Carpo M, Meucci N. Are there immunologically treatable motor neuron diseases? Amyotroph Lat Scler Other Motor Neuron Disord 2001;2(1 Suppl):S23-S30.
90. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology and neurobiology. Crit Rev Neurobiol 1999;13:45-82.
91. Orrell RW. Amyotrophic lateral sclerosis: copper/zinc superoxide dismutase (SOD1) gene mutations. Neuromuscul Dis 2000;10:63-68.
92. Orrell RW, Habgood JJ, Gardiner I, King AW, Bowe FA, Hallewell RA, Marklund SL, Greenwood J, Lane RJM, Debelleroche J. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology 1997;48:746-751.
93. Pamphlett R. Detection and cellular localization of enterovirus RNA sequence in spinal cord of patients with ALS. Neurology 2000;55:1420-1421.
94. Pasinelli P, Houseweart MK, Brown RH, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu/Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2000;97:13901-13906.
95. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis. Ann Neurol 1998;44:8819-8824.
96. Penfield W. Microglia and the process of phagocytosis in gliomas. Am J Pathol 1925;1:77-89.
97. Pioro EP. Antioxidant therapy in ALS. Amyotroph Lat Scler Other Motor Neuron Disord 2000;1(Suppl 4)5-15.
98. Prasad KN, Hovland AR, Larosa FG, Hovland PG. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc Soc Exp Biol Med 1998;21:120-125.
99. Przedborski S, Donaldson D, Jakowee M, Kish SJ, Guttman M, Rosoklija G, Hays AP. Brain superoxide dismutase, catalase and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol 1996;39:158-165.
100. Resnick DK, Graham SH, Dixon CE, Marion DW. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 1998;15:1005-1013.
101. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55:526-528.
102. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson S, Goto J, O'Regan JP, Deng HX. Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
103. Rosener M, Hahn H, Kranz M, Heeney J, Rethwilm A. Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. J Med Virol 1996;48:222-226.
104. Salazargrueso EF, Roos RP. Amyotrophic lateral sclerosis and viruses. Clin Neurosci 1996;3:360-367.
105. Sasaki S, Warita H, Abe K, Iwata M. Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with a G93A mutant SOD1 gene. J Neuropathol Exp Neurol 2001;60:839-846.
106. Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139:27-33.
107. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194-199.
108. Shaw CE, Enayat ZE, Chioza BA, Alchalabi A, Radunovic A, Powell JF, Leigh PN. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol 1998;43:390-394.
109. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Saski S, Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001;917:97-104.
110. Smith RG, Appel AH. Immunosuppression and antiinflammatory agents in ALS. Amyotroph Lat Scler Other Motor Neuron Disord 2000;1(4 Suppl):33-42.
111. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. J Biol Chem 1996;271:33157-33160.
112. Sola P, Merelli E, Levani M, Giovannetti R, Barozzi P. Human herpes virus 6 (HHV-6) in amyotrophic lateral sclerosis - a polymerase chain reaction (PCR) study. Eur J Neurol 1996;3:315-318.
113. Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J, Little S, Kramer R, Clemens J. Cytosolic phospholipase A(2) is induced in reactive glia following different forms of neurodegeneration. Glia 1999;27:110-128.
114. Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Dis 1995;5:457-465.
115. Tan E, Lynn DJ, Amato AA, Kissel JT, Rammohan KW, Sahenk Z, Warmolts JR, Jackson CE, Barohn RJ, Mendell JR. Immunosuppressive treatment of motor neuron syndrome. Attempts to distinguish a treatable disorder. Arch Neurol 1994;51:194-200.
116. Troost D, Van den Oord JJ, Vianney de Jong JMB. Immunohistochemical characteristics of the inflammatory infiltration in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 1990;16:401-410.
117. Tsuboi Y, Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1994;57:859-861.
118. Van Furth R. Current view on the mononuclear phagocyte system. Immunobiology 1982;161:178-185.
119. Vyth A, Timmer JG, Bossuyt PM, Louwerse ES, de Jong JM. Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants. J Neurol Sci 1996;139(Suppl):99-103.
120. Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990;82:132-134.
121. Woodall CJ, Riding MH, Graham DI, Clements GB. Sequences specific for enterovirus detected in spinal cord from patients with motor neurone disease. BMJ 1994;308:1541-1543.
122. Yang Y, Hentati A, Deng H-X, Dabbagh O, Saski T, Hirano M, Hung W-Y, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Humida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160-165.
123. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999;830:226-236.
124. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-1051.
125. Yasojima K, Schwab C, McGeer EG, McGeer PL. Upregulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 1999;154:927-936.
126. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology 2001;57:952-956.
127. Young HA, Hardy KJ. Role of interferon-y in immune cell regulation. J Leukoc Biol 1995;58:373-381.